Study guide
11.3 Investigator's Brochure, Instructions for Use & Reference Product Information
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
11.3 Investigator's Brochure, Instructions for Use & Reference Product Information
Key Takeaways Explain This Topic AI
The Investigator's Brochure (IB) is a comprehensive compilation of nonclinical and clinical data on the investigational product under ICH GCP E6 Section 7 and 21 CFR 312.55, designed to provide trial staff with a clear understanding of the scientific rationale, dosing, safety profile, and risk management.
The mandatory structural framework of an IB comprises eight core sections: Title Page, Table of Contents, Summary, Introduction, Physical/Chemical/Pharmaceutical Properties, Nonclinical Studies (pharmacology, PK, toxicology), Effects in Humans (PK, safety, efficacy), and Summary of Data and Guidance for the Investigator.
Section 7 of the IB (Summary of Data and Guidance for the Investigator) contains the definitive Reference Safety Information (RSI) table, which serves as the legal baseline for determining the 'expectedness' of serious adverse reactions for expedited regulatory reporting.
Sponsors are required to review the IB at least annually and revise it as new safety or efficacy data emerges; urgent significant safety findings must be communicated immediately to investigators and IRBs before formal annual IB reissue.
For already marketed, approved pharmaceutical products investigated within their approved indications, dosage, and patient population, the official approved Package Insert (Prescribing Information / SmPC) may substitute for an IB; however, studying a new indication, novel route, or higher dose requires an IB or formal supplement.
Last updated: October 2026
Investigator's Brochure (IB) Content, Annual Updates & Package Inserts
Core Regulatory Standard: The Investigator's Brochure (IB) is the central scientific and safety reference document in clinical drug development. Governed by ICH E6(R3) Appendix A — the Investigator's Brochure moved from Section 7 of E6(R2) to Appendix A of E6(R3), with the protocol taking Appendix B — the IB provides investigators, study coordinators, and Institutional Review Boards (IRBs) with the pharmacological, toxicological, and clinical context necessary to execute a clinical trial safely. On the ACRP-CP exam, candidates must understand the standard IB architecture, the critical regulatory function of the Reference Safety Information (RSI) , the annual update mandate, and the rules governing package insert substitution.
1. Purpose and Regulatory Foundation of the Investigator's Brochure
Under ICH E6(R3) Appendix A.1 , the Investigator's Brochure is defined as:
"A compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects." ┌───────────────────────────────────────────────────────────────────────────┐
- │ THE FOUR CORE FUNCTIONS OF AN IB │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. SCIENTIFIC RATIONALE: Explains the biological mechanism, target │
- │ engagement, and pharmacological rationale for clinical development. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. DOSE & REGIMEN JUSTIFICATION: Provides nonclinical and early PK/PD │
- │ data justifying starting doses, escalation schemes, and route of admin│
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 3. CLINICAL RISK MANAGEMENT: Details known toxicities, contraindications,│
- │ monitoring parameters, stopping rules, and overdose rescue protocols. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 4. SAFETY BENCHMARK (RSI): Establishes the official Reference Safety │
- │ Information used to assess the "expectedness" of adverse reactions. │
- └───────────────────────────────────────────────────────────────────────────┘
- 2. Standard Structural Architecture of the IB (ICH E6(R3) Appendix A.3)
ICH GCP E6 Section 7.3 specifies the minimum required sections and content that must be included in every Investigator's Brochure: ┌───────────────────────────────────────────────────────────────────────────┐
- │ ICH GCP E6 INVESTIGATOR'S BROCHURE STRUCTURE │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. TITLE PAGE & CONFIDENTIALITY STATEMENT │
- │ • Sponsor name, IP identity/code number, IB edition number, release │
- │ date, version history, and statement of confidentiality. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. TABLE OF CONTENTS │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 3. SUMMARY (1 to 2 pages) │
- │ • Executive overview of physical, chemical, nonclinical, and clinical │
- │ properties relevant to the current stage of development. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 4. INTRODUCTION │
- │ • Chemical/generic name, active ingredients, pharmacological class, │
- │ structural formula, and anticipated clinical therapeutic indication. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 5. PHYSICAL, CHEMICAL, AND PHARMACEUTICAL PROPERTIES & FORMULATION │
- │ • Description of drug substance, formulation, excipients, storage │
- │ conditions (temperature/humidity), stability, and reconstitution. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 6. NONCLINICAL STUDIES │
- │ • Nonclinical Pharmacology (in vitro receptor binding, PD mechanisms) │
- │ • Pharmacokinetics & Product Metabolism in Animals (absorption, ADME) │
- │ • Toxicology: Single-dose, repeat-dose, carcinogenicity, genotoxicity,│
- │ reproductive/developmental toxicity, and safety pharmacology. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 7. EFFECTS IN HUMANS │
- │ • Human Pharmacokinetics & Metabolism (ADME, bioavailability, half-life)│
- │ • Clinical Safety & Efficacy data across completed and ongoing trials │
- │ • Marketing Experience (commercial approvals or safety withdrawals) │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 8. SUMMARY OF DATA AND GUIDANCE FOR THE INVESTIGATOR │
- │ • Overall benefit-risk assessment, treatment of overdose, precautions │
- │ • THE REFERENCE SAFETY INFORMATION (RSI) TABLE │
- └───────────────────────────────────────────────────────────────────────────┘
- In-Depth Breakdown of Critical IB Sections
Section Regulatory Focus What the Study Team Looks For
Nonclinical Toxicology Animal safety margins, target organ toxicities, No Observed Adverse Effect Levels (NOAEL) Identification of potential human organ risks (e.g., hepatotoxicity, QT prolongation, bone marrow suppression)
Effects in Humans Cumulative clinical data, phase-by-phase safety, dose-limiting toxicities (DLTs) Real-world human tolerability, effective concentration ranges, known ADR frequencies
Guidance for Investigator Clinical management, stopping criteria, monitoring protocols, overdose antidotes Clear operational rules for dose reduction, pausing therapy, laboratory safety thresholds
3. The Reference Safety Information (RSI) Section
Within the Summary of Data and Guidance for the Investigator section lies the Reference Safety Information (RSI) —the most legally significant section for pharmacovigilance operations. ┌───────────────────────────────────────────────────────────────────────────┐
- │ THE CRITICAL FUNCTION OF THE RSI │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ WHAT IS THE RSI? │
- │ • The formal, approved list of expected Serious Adverse Drug Reactions │
- │ (SARs) associated with the investigational product. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ HOW RSI DETERMINES SUSAR EXPEDITED REPORTING: │
- │ • When a Serious Adverse Reaction occurs: │
- │ - If listed in the RSI -> EXPECTED SAR (Reported in annual DSUR). │
- │ - If NOT listed in the RSI -> UNEXPECTED SAR (SUSAR!) -> Triggers │
- │ mandatory expedited 7-day or 15-day regulatory reporting to FDA/IRB! │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ STRICT REGULATORY RULES FOR RSI: │
- │ 1. Animal toxicities CANNOT be used to make an event expected in humans. │
- │ 2. Class effects CANNOT be listed as expected unless observed with IP. │
- │ 3. The RSI table must specify the EXACT nature, severity, and frequency. │
- └───────────────────────────────────────────────────────────────────────────┘
What Constitutes an "Unexpected" Event against the RSI?
Even if an adverse reaction is mentioned in the body of the IB, it is classified as Unexpected for expedited reporting purposes if:
It is not explicitly included in the RSI table/section ;
It occurs at a higher severity or intensity than listed in the RSI (e.g., RSI lists "Grade 1-2 transaminitis," but patient develops "Grade 4 acute liver failure");
It exhibits greater specificity than described (e.g., RSI lists "rash," but patient develops "Toxic Epidermal Necrolysis");
It results in an unexpected outcome (e.g., RSI lists "reversible bronchospasm," but event is "fatal").
4. Annual Review, Updates & Site Implementation Workflow
Under ICH GCP E6 Section 7.1 and 21 CFR 312.55 , the sponsor must review the Investigator's Brochure at least annually and update it as significant new information becomes available. ┌───────────────────────────────────────────────────────────────────────────┐
- │ IB ANNUAL REVIEW & REVISION LIFECYCLE │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ ANNUAL SPONSOR REVIEW (ICH E6(R3) Appendix A.1): │
- │ • Sponsor compiles all new nonclinical data, clinical trial safety/PK/PD │
- │ findings, and worldwide regulatory updates. │
- │ • If significant new data exists -> Issue revised edition (e.g., Ver 4.0)│
- │ • If NO new significant data -> Document annual review; maintain current.│
- ├───────────────────────────────────────────────────────────────────────────┤
- │ EMERGENCY MID-YEAR SAFETY REVISIONS: │
- │ • If critical new safety risks emerge mid-year (e.g., unexpected deaths, │
- │ black-box toxicity, or hold), the sponsor CANNOT wait for annual review│
- │ • Sponsor must IMMEDIATELY issue a "Dear Investigator" Safety Alert, │
- │ followed promptly by an official IB Addendum or updated version. │
- └───────────────────────────────────────────────────────────────────────────┘
- Site-Level Action Steps upon Receiving a Revised IB Edition
When an investigative site receives a new edition of the Investigator's Brochure from the sponsor, the study coordinator and Principal Investigator must execute a strict operational workflow: ┌───────────────────────────────────────────────────────────────────────────┐
- │ SITE WORKFLOW: NEW IB IMPLEMENTATION │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. PRINCIPAL INVESTIGATOR REVIEW │
- │ • PI and sub-investigators thoroughly read the updated IB. │
- │ • Document training on the Staff Training Log / DOAL. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. INSTITUTIONAL REVIEW BOARD (IRB) SUBMISSION │
- │ • Submit the new IB edition (with track-changes summary) to the IRB. │
- │ • Maintain IRB acknowledgment / approval letter in the ISF. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 3. INFORMED CONSENT EVALUATION & RE-CONSENT │
- │ • Assess whether new risks or adverse reactions impact subject safety │
- │ • Inform participants promptly; assess whether re-consent is needed │
- │ • Re-consent with the IRB-approved revised ICF where it is needed │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 4. INVESTIGATOR SITE FILE (ISF) ARCHIVING │
- │ • File the active IB in the regulatory binder (ISF). │
- │ • Mark previous superseded editions as "SUPERSEDED" and archive. │
- └───────────────────────────────────────────────────────────────────────────┘
5. Package Inserts / Summary of Product Characteristics (SmPC) as IB Substitutes
In specific clinical research contexts, a full Investigator's Brochure may not be required, and an official commercial Package Insert (Prescribing Information / USPI) or European Summary of Product Characteristics (SmPC) may be utilized. ┌───────────────────────────────────────────────────────────────────────────┐
- │ WHEN CAN A PACKAGE INSERT SUBSTITUTE FOR AN IB? │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ PERMISSIBLE (Package Insert Allowed as IB Substitute): │
- │ • The investigational product is already APPROVED and MARKETED; AND │
- │ • The clinical trial investigates the drug strictly WITHIN its approved: │
- │ - Indication and patient population; │
- │ - Dosage strength and administration schedule; │
- │ - Route of administration and formulation. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ PROHIBITED (Full IB or Formal IB Supplement REQUIRED): │
- │ • Studying an approved drug for an UNAPPROVED / NEW INDICATION; │
- │ • Using a NOVEL DOSAGE STRENGTH or accelerated escalation scheme; │
- │ • Administering via a NOVEL ROUTE (e.g., intrathecal instead of oral); │
- │ • Studying a NEW POPULATION (e.g., pediatric trial for adult-only drug); │
- │ • Unapproved drug-combination regimens with potential synergistic tox. │
- └───────────────────────────────────────────────────────────────────────────┘
- 6. Realistic Clinical Scenario: IB Update and Risk-Benefit Re-Evaluation
Clinical Scenario: Dr. Marcus Thorne is the PI for a Phase 3 randomized, double-blind oncology trial evaluating BL-909 combined with standard chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). In November, the sponsor releases Investigator's Brochure Edition 5.0 , replacing Edition 4.0.
Key Changes in Edition 5.0: Review of Section 7 (Effects in Humans) and Section 8 (Guidance for the Investigator / RSI) reveals that in an ongoing parallel colorectal cancer study, 4 out of 120 patients exposed to BL-909 developed severe Grade 3/4 interstitial lung disease (ILD) / pneumonitis, including one fatal case. The sponsor updates the RSI table to include Drug-Induced Pneumonitis as an expected serious adverse reaction and introduces mandatory baseline high-resolution chest CT scans and pulmonary symptom questionnaires.
Operational Execution at Dr. Thorne's Site:
PI & Staff Training: Dr. Thorne and the study coordinators review Edition 5.0. Dr. Thorne signs the acknowledgment form, and the study team documents an in-service training session on the site training log.
IRB Submission: The site regulatory coordinator submits IB Edition 5.0, along with the sponsor's Summary of Changes document, to the reviewing central IRB within 5 business days.
Protocol & Informed Consent Revision: The sponsor issues Protocol Amendment 3 and a revised Informed Consent Form (ICF Version 3.0) incorporating the new pneumonitis risk language and required CT monitoring. Once the IRB approves ICF Version 3.0, Dr. Thorne's team re-consents all 14 actively enrolled subjects at their next scheduled clinic visit before administering further study treatment.
ISF Management: The regulatory coordinator places IB Edition 5.0 into Section 4 of the Investigator Site File (ISF), stamps IB Edition 4.0 as "SUPERSEDED - Version 4.0 - Date: 15-Nov-2026" , and archives it in the historical regulatory binder.